Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00455260
Other study ID # GH-VD-102
Secondary ID
Status Completed
Phase Phase 1
First received April 2, 2007
Last updated August 30, 2013
Start date April 2007

Study information

Verified date April 2009
Source Teva Pharmaceutical Industries
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of HealthUkraine: Ministry of Health
Study type Interventional

Clinical Trial Summary

This study aims to examine the safety, tolerability and pharmacokinetics of transdermal delivery of human Growth Hormone (hGH or somatropin) using the ViaDerm device in adult patients with Growth Hormone Deficiency Syndrome.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date
Est. primary completion date October 2007
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria:

Ages Eligible for Study: 20 Years - 60 Years, Genders Eligible for Study: Both

1. Clinical diagnosis of Adult Growth Hormone Deficiency (AGHD) meeting one of the following criteria:

- Three or more additional pituitary hormone deficiencies, based on well documented medical history from up to 10 years prior to screening, and/or serum IGF-1 levels below 2 SD from normal level, measured up to 4 months prior to screening.

- One or two additional pituitary hormone deficiencies with one GH stimulating test performed within 10 years prior to screening: Insulin Tolerance test with GH levels less than 5.1 µg/L or ARG-GHRH with GH levels less than 4.1 µg/L.

- Isolated GH deficient subjects with two well-documented GH stimulating tests performed within 10 years prior to screening. Insulin Tolerance test with GH levels less than 5.1 µg/L or ARG-GHRH with GH levels less than 4.1 µg/L.

- In childhood onset AGHD, confirmation of GHD following attainment of full height.

2. Subjects using hormone replacement therapy for additional pituitary deficits must be on an optimized treatment regimen for at least three months prior to screening.

3. Willing and able to provide written informed consent prior to performing any study procedures.

Exclusion Criteria:

1. GH therapy within one month prior to study entry.

2. For female subjects: pregnancy or lactation or use of oral contraception or unacceptable method of contraception throughout the study.

3. Active acromegaly in the last 5 years.

4. Carpal tunnel syndrome.

5. Prader-Willi syndrome.

6. Active Cushing's syndrome within the last 12 months.

7. Non-compliance for upper arm SC injection or patch application.

8. Skin color or tattoo that would not enable detection of erythema.

9. Upper extremities with skin marks, bruises, cuts, abrasions on the upper arm.

10. Dense and dark hair growth on upper extremities.

11. History of skin hypersensitivity and/or allergies.

12. Known hypersensitivity to somatropin or mannitol

13. Evidence of active malignancy.

14. Previous use of chemotherapy, immunosuppressive or radiation therapy, except for treatment of pituitary disease.

15. Serum glucose (fasting) > 126 mg/dl.

16. Known or suspected HIV-positive subjects or subjects with advanced diseases such as AIDS, Hepatitis C, Hepatitis B or tuberculosis.

17. Subjects who, based on the investigator's judgment, have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. Conditions may include cardiovascular, vascular, pulmonary, hepatic, renal, or neurological disease, as determined by medical history, physical examination, laboratory tests or ECG.

18. BMI < 19 and = 35 kg/m2.

19. Weight reducing drugs or appetite suppressants.

20. Estrogen replacement therapy except transdermal patch.

21. Any psychological condition which may influence the compliance with the study requirements.

22. Unstabilized antidepressant or antipsychotic medication therapy within 2 months prior to screening.

23. Subjects with a known history of alcohol abuse.

24. Subjects who received blood or plasma derivatives in the three months preceding screening.

25. Subjects who donated blood in the preceding three months of screening or intend to make a blood donation during the study, or within the three months following the study completion.

26. Subjects who have participated in another clinical study of any kind (drug or device) in the one month prior to screening.

27. Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
hGH-ViaDerm™ System (hGH or somatropin)
transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
Device:
hGH-ViaDerm™ System
The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin). The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Teva Neuroscience, Inc. Teva Pharmaceutical Industries, TransPharma Medical

Outcome

Type Measure Description Time frame Safety issue
Primary AE 36 days Yes
Primary Laboratory values 36 days Yes
Primary Vital signs 36 days Yes
Primary ECG 36 days Yes
Primary Patch application site reaction: Skin irritation- erythema, edema 36 days Yes
Primary Patch application site reaction: Pain - Visual Analogue Scale 36 days Yes
Primary Proportion of subjects (%) who discontinue the study 36 days Yes
Primary Proportion of subjects (%) who discontinue the study due to AEs 36 days Yes
Primary Pharmacokinetics: Somatropin exposure including Cmax, Tmax, AUC, AUC, Ke, and T1/2. 36 days No
Primary Pharmacodynamics: Human IGF-1 levels and AUC. 36 days No
See also
  Status Clinical Trial Phase
Recruiting NCT02243852 - Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21) N/A
Completed NCT01440686 - Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Phase 1
Completed NCT00990340 - Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Phase 4
Completed NCT00149708 - Consequence of Lifetime Isolated Growth Hormone Deficiency N/A
Completed NCT00235599 - The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children. N/A
Completed NCT00459940 - The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients N/A
Completed NCT01157793 - A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Phase 4
Completed NCT00004365 - Study of Pituitary Size and Function in Familial Dwarfism of Sindh N/A
Recruiting NCT00227253 - Chromosome 18 Clinical Research Center
Recruiting NCT04121780 - Growth Hormone Replacement Therapy for Retried Professional Football Players Phase 2
Completed NCT02934399 - Dynamic Hormone Diagnostics in Endocrine Disease
Completed NCT01090778 - Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I) Phase 2
Completed NCT00965484 - Genotropin Study Assessing Use of Injection Pen Phase 3
Completed NCT01062529 - Peripheral Metabolic Effects of Somatostatin N/A
Completed NCT00616278 - National Cooperative Growth Study in CKD N/A
Completed NCT02693522 - Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency Phase 3
Recruiting NCT02908958 - Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Phase 4
Terminated NCT01243892 - A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device N/A
Withdrawn NCT00638287 - Inter-Assay Growth Hormone and IGF-I Variability N/A
Completed NCT00957671 - Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Phase 4